Abstract 2124
Background
Varlitinib (VAR, ASLAN001) is a potent pan-HER oral tyrosine kinase inhibitor, with efficacy in EGFR mutant and HER2 over-expressing tumours. We evaluated the safety, tolerability and maximum tolerated dose (MTD) of VAR with CAPOX (COX) and mFolfox6 (FOL), in pts with advanced solid tumours.
Methods
Eligible pts had advanced solid tumours, ECOG performance status (PS) 0-1 and adequate organ function. Colorectal cancer (CRC) with RAS/RAF mutations were excluded. COX (Capecitabine 850mg/m2 BID D1-D14 with oxaliplatin (OX) 130mg/m2 IV D1, Q21 days) or mFolfox6 (5-FU 400mg/m2 IV bolus D1 and 2400mg/m2 over 46 hrs with OX 85mg/m2 IV D1, Leucovorin 400mg/m2 IV D1, Q14 days) was given with VAR 200-400mg BID. Maximum 6 cycles COX or 9 cycles FOL, followed by VAR alone. Dose-limiting toxicity (DLT) period was 2 cycles.
Results
30 pts were enrolled, 9 COX and 21 FOL arm. 15 (52%) CRC (all prior OX), 6 (21%) cholangiocarcinoma (CC), 3 (10%) gallbladder cancer and 6 (20%) others. Sex M/F 13/17, median age (range), PS, lines of prior chemo was 62yrs (36-71), 1(0-1) and 3.5(0-7) respectively. 28 pts were evaluable for MTD. MTD of VAR was 300mg/BID when given with FOL or COX.Table: 430P
| Dose | Pt enrolled/ evaluable | DLT |
|---|---|---|
| COX + VAR 400mg/BID | 3/2 | G3 Fatigue x2 |
| COX + VAR 300mg/BID | 6/6 | G3 Fatigue |
| FOL + VAR 400mg/BID | 4/4 | G4 Transaminitis, G3 Raised Bilirubin |
| FOL + VAR 300mg/BID | 11/9 | G4 Encephalopathy, G3 Rash |
| FOL + VAR 200mg/BID | 6/6 | G3 Encephalopathy |
Grade 3/4 AEs (occurring ≥ 5%): neutropenia 5 (17%), fatigue 3(10%), transaminitis 2(7%), diarrhoea 2(7%), febrile neutropenia 2(7%), transient metabolic encephalopathy 2(7%). Of 28 pts evaluable for response, 3 (11%) had PR and 16 (57%) SD. Disease control rate (PR+SD) for ≥ 12wks was 13 (46%). 5 (18%) had long PFS (223-645 days), comprising a gallbladder and CRC (both HER2-overexpressing, prior platinum), CC, bladder and CRC (prior OX and cetuximab). PK analysis did not show VAR accumulation. Plasma cell free DNA and HER pathway inhibition results will be presented later.
Conclusions
MTD for VAR with COX and FOL was 300mg/BID. Durable efficacy was seen in biliary cancers and CRC. ASLAN pharmaceuticals and the Singapore National Medical Research Council supported this study.
Clinical trial identification
NCT02435927.
Legal entity responsible for the study
National Cancer Centre, Singapore.
Funding
Aslan Pharmaceuticals.
Editorial Acknowledgement
Disclosure
M. Ng: Member: Aslan Pharmaceuticals advisory board; Speaker and research funding: Industry associated funding. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract